MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

Inicio・Lista de Acciones・Editas Medicine Inc

Editas Medicine Inc

Abierto

SectorSanidad

3.36 4.35

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.19

Máximo

3.54

Métricas clave
By Trading Economics
Ingresos	19M -5.6M
Ventas	17M 25M
BPA	-0.06
Margen de beneficios	-22.715
Empleados	87
EBITDA	17M -5.3M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+75.17% upside

Dividendos
By Dow Jones
Próximas Ganancias	11 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	40M 266M
Apertura anterior	-0.99
Cierre anterior	3.36

Noticias sobre sentimiento de mercado

By Acuity

60%

40%

301 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.33 / 1.54 Soporte y Resistencia

Editas Medicine Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 abr 2026, 23:25 UTC

Noticias de Eventos Importantes

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 abr 2026, 22:45 UTC

Noticias de Eventos Importantes

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 abr 2026, 18:03 UTC

Ganancias

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 abr 2026, 23:58 UTC

Ganancias

Review & Preview: Earnings Time -- Barrons.com

13 abr 2026, 23:49 UTC

Charlas de Mercado

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 abr 2026, 23:33 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 abr 2026, 23:20 UTC

Charlas de Mercado

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 abr 2026, 23:01 UTC

Ganancias

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 abr 2026, 23:01 UTC

Ganancias

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 abr 2026, 23:01 UTC

Ganancias

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 abr 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 abr 2026, 21:53 UTC

Ganancias

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 abr 2026, 21:53 UTC

Ganancias

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 abr 2026, 21:53 UTC

Ganancias

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 abr 2026, 21:53 UTC

Ganancias

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 abr 2026, 21:26 UTC

Noticias de Eventos Importantes

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 abr 2026, 21:23 UTC

Ganancias

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 abr 2026, 21:16 UTC

Ganancias

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 abr 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

13 abr 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

13 abr 2026, 20:34 UTC

Ganancias

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 abr 2026, 20:34 UTC

Ganancias

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 abr 2026, 20:34 UTC

Ganancias

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 abr 2026, 19:59 UTC

Charlas de Mercado

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 abr 2026, 19:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 abr 2026, 19:27 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Correction to Precious Metals Market Talk on April 9

13 abr 2026, 19:14 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 abr 2026, 18:59 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 abr 2026, 18:59 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 abr 2026, 18:43 UTC

Charlas de Mercado

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Comparación entre iguales

Cambio de precio

Editas Medicine Inc previsión

Precio Objetivo

By TipRanks

75.17% repunte

Estimación a 12 Meses

Media 5.15 USD 75.17%

Máximo 8 USD

Mínimo 4 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Editas Medicine Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Editas Medicine Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.33 / 1.54Soporte y Resistencia

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Sentimiento

By Acuity

301 / 348 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.